Lynd, Larry D - University of British Columbia - Faculty of Pharmaceutical Sciences

个人简介

Dr. Larry Lynd received his BSP in 1986 from the University of Saskatchewan and his PhD in the Department of Health Care and Epidemiology at UBC in 2002. He then completed a two-year post-doctoral fellowship in health economics with Dr. Bernie O'Brien at McMaster University. Currently, Dr. Lynd is a professor and director of the Collaboration for Outcomes Research and Evaluation (CORE) at the UBC Faculty of Pharmaceutical Sciences, scientist at the Centre for Clinical Epidemiology and Evaluation, scientist at the Centre for Health Evaluation and Outcomes Sciences, scholar at the Peter Wall Institute of Advanced Studies, and associate of the UBC School of Population and Public Health. Dr. Lynd has made significant contributions serving on a number of committees, including chair of the Health Canada Special Advisory Committee on Non-Prescription Drugs, Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee, and the BC PharmaNet Data Stewardship Committee.

研究领域

Dr. Lynd conducts state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis. Through his involvement in the BC Ministry of Health Expensive Drug for Rare Diseases Committee, to which he was appointed for a second term for his health economics expertise, he has identified significant knowledge gaps relating to policy and decision-making associated with orphan drugs and personalized medicine. As such, he was successful in receiving a Canadian Institutes of Health Research team grant as the principal investigator for a national, multi-disciplinary team of economists, epidemiologists, policy researchers, ethicists, lawyers, clinicians, and knowledge users to develop new knowledge relating to funding and reimbursement of expensive drugs for rare diseases. One of Dr. Lynd's primary areas of interest is in respiratory diseases, specifically asthma and chronic obstructive pulmonary disease. Because the evaluation of health outcomes has no geographic or disease-specific boundaries, he is also involved in a number of international studies that have the potential to influence policy in countries such as Rwanda and Cambodia. Overall, the ultimate research goal for Dr. Lynd is the translation of knowledge into improved patient outcomes and the health care decision-making process.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Why orphan drug coverage reimbursement decision-making needs patient and public involvement, Douglas, Conor M. W., Wilcox Elizabeth, Burgess Michael, and Lynd Larry D. , Health Policy, Jan-01-2015, (2015) Quantifying preferences for asthma control in parents and adolescents using best-worst scaling., Ungar, Wendy J., Hadioonzadeh Anahita, Najafzadeh Mehdi, Tsao Nicole W., Dell Sharon, and Lynd Larry D. , Respir Med, 2014 Jun, Volume 108, Issue 6, p.842-51, (2014) Crowdfunding drug development: the state of play in oncology and rare diseases., Dragojlovic, Nick, and Lynd Larry D. , Drug Discov Today, 2014 Nov, Volume 19, Issue 11, p.1775-80, (2014) Comparison of HRQL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis., Sweeney, Katie, Grubisic Maja, Marra Carlo A., Kendall Richard, Li Linda C., and Lynd Larry D. , J Arthroplasty, 2013 Oct, Volume 28, Issue 9 Suppl, p.187-90, (2013) Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study., Bedouch, Pierrick, Sadatsafavi Mohsen, Marra Carlo A., J FitzGerald Mark, and Lynd Larry D. , PLoS One, 2012, Volume 7, Issue 12, p.e50949, (2012)